LTCI NOW is created by Imulan to inform cat owners about fast, new treatment program for FIV and FELV
New York, N.Y. (PRWEB) November 4, 2009 -- IMULAN BioTherapeutics, LLC has developed the LTCI NOW program in an effort to educate cat owners about the new, fast way to get LTCI for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Like Human Immunodeficiency Virus (HIV), FIV and FeLV are retroviral infections that can cause immunosuppression.
The LTCI NOW program will not only inform pet owners about the first and only USDA-conditionally approved treatment for FIV and FeLV, but also provide a truly simple and fast way to either obtain the pioneered product through their current veterinarian or through a network of current LTCI-using veterinarians across the country (Imulan’s ‘Treatment Network’) . LTCI’s sole focus is to make things as easy as possible on the pet owner; all they need to do is go to the website, and provide their veterinarian with the LTCI NOW brochure – the vet takes it from there. LTCI, or Lymphocyte T-Cell Immunomodulator, is only available through veterinarians, and is a major step forward in combating these highly serious and potentially fatal feline illnesses, which can lead to severe immune suppression (like HIV), anemia, and increased risk of other infections. In addition to fostering awareness about the feline illnesses and treatment with LTCI, IMULAN’s veterinarians will also offer free case consultations with the pet owner’s veterinarian.
According to Dr. Craig Woods, CEO of IMULAN, "IMULAN's LTCI NOW program is designed to make the process of getting LTCI for cats infected with FeLV and FIV as easy as possible. IMULAN has streamlined the process because time is of the essence for many of these patients, who often are very sick. FeLV and FIV remain devastating diseases, and the more veterinarians and owners are aware of the available options, the more effective our profession will be at managing these diseases.”
The LTCI NOW Program was established to further the awareness of these feline diseases. The goal for the program is to make the process as simple as possible for pet owners, allowing them easy access to information LTCI so they are informed in discussions with their veterinarian.
IMULAN BioTherapeutics, LLC is a privately held bioscience company, working to develop immune-based treatments for various life threatening animal diseases. With technologies that are able to modulate cells that coordinate immune response and inflammation, IMULAN is a leader in developing first-in-class technologies for veterinary medicine. LTCI, approved by the United States Department of Agriculture, is IMULAN’s first commercial product manufactured by T-Cyte Therapeutics, Inc. LTCI has received a conditional license from the United States Department of Agriculture, additional efficacy and potency studies are underway.
Read the full story at http://www.prweb.com/releases/2009/11/prweb3148704.htm.
Copyright©2009 Vocus, Inc.
All rights reserved